AbbVie’s Skyrizi Gets FDA Green Light for Pediatrics: A Game Changer for Growth Investors
AbbVie (ABBV) stock rose 3.44% following FDA approval for Skyrizi's pediatric use, signaling potential revenue growth.
CRISPR Therapeutics and Vertex Pharmaceuticals Gain FDA Approval: What It Means for Investors
CRISPR Therapeutics and Vertex Pharmaceuticals see significant market movement following FDA approval for pediatric gene therapy.
CRISPR and Vertex Shares Surge After FDA Approves Casgevy for Younger Patients
CRSP shares jumped 8% following FDA approval of Casgevy for children ages 2 and up, signaling a significant market opportunity.
Zymeworks' $929 Million Acquisition of Theravance Biopharma: Implications for Investors
Zymeworks' strategic $929M acquisition of Theravance Biopharma at $17/share highlights key trends in the biotech sector.
Viridian Therapeutics Achieves Milestone with FDA Approval of Lumvoa: What Investors Need to Know
Viridian Therapeutics' Lumvoa receives FDA approval, boosting stock by 6% in after-hours trading. Insights on UBS rating and implications fo…
Larimar Therapeutics Faces Setback with Partial BLA Submission for Nomlabofusp
Larimar Therapeutics' stock slides after a partial BLA submission delays FDA review timelines for nomlabofusp.
Capricor Therapeutics: FDA Advisory Meeting for Duchenne Therapy on the Horizon
Capricor Therapeutics seeks FDA approval for Deramiocel, a promising cell therapy for Duchenne muscular dystrophy, backed by five-year data.
Replimune's FDA BLA Acceptance: A Game Changer for Investors?
Replimune's FDA acceptance of its BLA for RP1 signals potential growth for investors as regulatory hurdles are cleared.
Insurance Coverage Concerns for GLP-1 Weight Loss Pills: What Investors Should Know
As consumer demand for GLP-1 weight-loss pills surges, insurance coverage limitations may impact revenue for $NVO and $LLY.
Replimune's FDA BLA Resubmission: A Game-Changer for Biotech Investors
Replimune's resubmission acceptance by the FDA could redefine investor sentiment and market dynamics for $REPL.
Aptorum Group's Strategic Move in Alzheimer's Biomarkers: A Game Changer for Investors?
Aptorum Group's collaboration with AlzLabs could reshape Alzheimer's diagnostics and impact the small-cap pharma market.
AbbVie’s $10.9 Billion Bet on Apogee: What It Means for Investors
AbbVie's $10.9 billion acquisition of Apogee Therapeutics reshapes its pipeline and reflects broader M&A trends in pharma.